Nuclear Medicine and Laboratory Data
| Parameter | Group 1: THW (n = 42) | Group 2: rhTSH (n = 45) | P |
|---|---|---|---|
| Pre-RRA 131I scanning activity | 72.2 ± 92.5 MBq | 90.7 ± 62.9 MBq | 0.01 |
| (1.95 ± 2.5 mCi) | (2.45 ± 1.7 mCi) | ||
| Baseline TSH | N/A | 6.0 ± 9.5 U/L | N/A |
| Baseline free T4 | 0.15 ± 0.16 pg/mL | 1.5 ± 0.46 pg/mL | <0.001 |
| Stimulated TSH | 97.5 ± 50 U/L | 105.1 ± 45.4 U/L | 0.28 |
| Stimulated Tg* | 6 ng/mL | 3 ng/mL | 0.04 |
| 24-h uptake pre-RRA* | 1.65% | 0.9% | 0.05 |
| 24-h uptake post-RRA* | 0.25% | 0.17% | 0.19 |
| Stimulated Tg post-RRA* | 0.65 ng/mL | 0.5 ng/mL | 0.48 |
| Distant metastasis on DxWBS | 4 | 2 | 0.26 |
| Distant metastasis on RxWBS | 7 | 4 | 0.35 |
| 131I ablation activity | 4.77 ± 2.74 GBq | 4.07 ± 2.41 GBq | 0.26 |
| (128.9 ± 74 mCi) | (110.4 ± 65 mCi) |
↵* Median.
N/A = not applicable; RxWBS = whole-body scan after therapy.